sm-8668 and Leukopenia

sm-8668 has been researched along with Leukopenia* in 2 studies

Other Studies

2 other study(ies) available for sm-8668 and Leukopenia

Article	Year
Efficacy of SCH 39304 in treatment of experimental invasive aspergillosis. Antimicrobial agents and chemotherapy, 1991, Volume: 35, Issue:10 The efficacy of SCH 39304 (SCH) against Aspergillus fumigatus was assessed with an immunosuppressed, temporarily leukopenic rabbit model of invasive aspergillosis. Therapy with SCH at 10 or 15 mg/kg of body weight per day was begun 24 h after lethal challenge and compared with therapy with amphotericin B at 1.5 mg/kg/day. Compared with untreated controls, SCH reduced mortality and also reduced the tissue burden of A. fumigatus 100- to 1,000-fold in liver, kidney, and lung tissues. SCH at 15 mg/kg/day and amphotericin B eliminated A. fumigatus in liver, kidney, and lung tissues. In addition, both dosages of SCH significantly eliminated the organism from brain tissues, compared with controls. Both SCH and amphotericin B decreased or eliminated circulating aspergillus antigen. These results show that new azoles can be as effective as amphotericin B in eradicating the organism from tissues and offer promise in improving the treatment of invasive aspergillosis. Topics: Amphotericin B; Animals; Antifungal Agents; Antigens, Fungal; Aspergillosis; Enzyme-Linked Immunosorbent Assay; Immunosuppression Therapy; Leukopenia; Rabbits; Triazoles	1991
In vitro and in vivo activities of Sch 39304, fluconazole, and amphotericin B against Histoplasma capsulatum. Antimicrobial agents and chemotherapy, 1990, Volume: 34, Issue:4 The antifungal activities of amphotericin B and two triazoles, Sch 39304 and fluconazole, were tested against Histoplasma capsulatum. In this study Sch 39304 compared favorably with amphotericin B in treating histoplasmosis in normal and leukopenic mice, whereas fluconazole was much less active. The differences in the efficacies of the triazoles appeared to be due to differences in their pharmacokinetics and the dosage schedule that was used. For amphotericin B there was a good correlation between in vitro and in vivo efficacy, but this was not true of the triazole derivatives. These results further demonstrate that, with the methods used in this study, in vitro susceptibility testing of triazoles may not be predictive of in vivo activity against isolates of H. capsulatum. Topics: Amphotericin B; Animals; Antifungal Agents; Female; Fluconazole; Histoplasma; Histoplasmosis; Leukopenia; Mice; Microbial Sensitivity Tests; Triazoles	1990

Article

Year

Efficacy of SCH 39304 in treatment of experimental invasive aspergillosis.

Antimicrobial agents and chemotherapy, 1991, Volume: 35, Issue:10

The efficacy of SCH 39304 (SCH) against Aspergillus fumigatus was assessed with an immunosuppressed, temporarily leukopenic rabbit model of invasive aspergillosis. Therapy with SCH at 10 or 15 mg/kg of body weight per day was begun 24 h after lethal challenge and compared with therapy with amphotericin B at 1.5 mg/kg/day. Compared with untreated controls, SCH reduced mortality and also reduced the tissue burden of A. fumigatus 100- to 1,000-fold in liver, kidney, and lung tissues. SCH at 15 mg/kg/day and amphotericin B eliminated A. fumigatus in liver, kidney, and lung tissues. In addition, both dosages of SCH significantly eliminated the organism from brain tissues, compared with controls. Both SCH and amphotericin B decreased or eliminated circulating aspergillus antigen. These results show that new azoles can be as effective as amphotericin B in eradicating the organism from tissues and offer promise in improving the treatment of invasive aspergillosis.

Topics: Amphotericin B; Animals; Antifungal Agents; Antigens, Fungal; Aspergillosis; Enzyme-Linked Immunosorbent Assay; Immunosuppression Therapy; Leukopenia; Rabbits; Triazoles

1991

In vitro and in vivo activities of Sch 39304, fluconazole, and amphotericin B against Histoplasma capsulatum.

Antimicrobial agents and chemotherapy, 1990, Volume: 34, Issue:4

The antifungal activities of amphotericin B and two triazoles, Sch 39304 and fluconazole, were tested against Histoplasma capsulatum. In this study Sch 39304 compared favorably with amphotericin B in treating histoplasmosis in normal and leukopenic mice, whereas fluconazole was much less active. The differences in the efficacies of the triazoles appeared to be due to differences in their pharmacokinetics and the dosage schedule that was used. For amphotericin B there was a good correlation between in vitro and in vivo efficacy, but this was not true of the triazole derivatives. These results further demonstrate that, with the methods used in this study, in vitro susceptibility testing of triazoles may not be predictive of in vivo activity against isolates of H. capsulatum.

Topics: Amphotericin B; Animals; Antifungal Agents; Female; Fluconazole; Histoplasma; Histoplasmosis; Leukopenia; Mice; Microbial Sensitivity Tests; Triazoles

1990